Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II studyStefano Cascinu, Michela Cinquini, Rossana Berardi et al.|Digestive and Liver Disease|2013Cited by 52
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)Benedetta Pellegrino, Antonino Musolino, Luigi Cavanna et al.|ESMO Open|2021Cited by 24
Abstract P1-14-05: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE Trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)Antonino Musolino, Andrea Ardizzoni, Luca Boni et al.|Cancer Research|2019Cited by 2
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).Antonino Musolino, Filippo Montemurro, Rossana Berardi et al.|Journal of Clinical Oncology|2017Cited by 0